Answers are grounded in this paper and cite their sources.
Alzheimer’s disease (AD) remains a significant global health challenge, necessitating the exploration of novel therapeutic strategies. AD is a neurodegenerative disease characterized by the formation of amyloid-β (Aβ) plaques and neurofibrillary tangles composed of tau protein. It is stated to be a cause of multiple mechanistic pathways and biochemical events, and hence, targeting only one mechanism at a time cannot suffice for all-round therapy. A multi-target drug ligand strategy can thus be employed in such a setting to modulate multiple drug targets simultaneously. Glycogen synthase kinase-3β (GSK-3β) is an enzyme involved in tau hyperphosphorylation, neuroinflammation, maintaining neuronal plasticity, and various cell processes. Thus, inhibiting GSK-3β itself may help in the control of some of the key factors stated to be responsible for Alzheimer’s disease pathophysiology. This review comprehensively evaluates the potential of GSK-3β inhibitors as multi-target drug ligands in AD therapeutics. We discuss the molecular mechanisms of GSK-3β in AD pathology and review the preclinical and clinical evidence supporting the efficacy of GSK-3β inhibitors in ameliorating cognitive decline and pathological hallmarks of AD. Furthermore, we explore the challenges associated with targeting GSK-3β, such as selectivity, blood–brain barrier penetration, and adverse effects. Additionally, we highlight recent advances in the development of novel GSK-3β inhibitors with improved pharmacokinetic properties and multitargeting capabilities. Finally, we discuss the future directions and potential clinical implications of GSK-3β inhibitors as multi-target drug ligands in the complex landscape of AD therapeutics.
No takes yet. Share an insight, caveat, or question.
Nachiket Jitendra Joshi (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: